Abstract: In some aspects the disclosure relates to recombinant adeno-associated virus (rAAV) vectors and rAAVs (e.g., viral particles) engineered to express a transgene comprising an inhibitory nucleic acid (e.g., an artificial miRNA, amiRNA) having a pri-miRNA scaffold and a guide strand that targets a human target gene.

Abstract: A shoe sole having an energy absorbing lattice structure and method of making thereof is disclosed. The energy absorbing structure comprises an energy absorbing lattice structure having an irregular, but not random, lattice pattern. The irregular lattice pattern of the energy absorbing lattice structure may be a Voronoi cell pattern, which may be derived from a biological lattice such as bovid skull horncore morphology for example. The bioinspired lattices of the shoe sole may be configured/tailored for two purposes: 1) large energy absorption properties and 2) biomechanically controlling the position of the foot to further control joint (e.g., ankle, knee, hip, spine) loading, forces, and pain.

Abstract: A versatile method to create hydrophobic 3-D surfaces with complex hierarchical microstructures that mimic the patterns found on springtail skin is disclosed. The method innovatively merges two fixed-spacing patterns at different scales to create patterns with varying spacing but does not require precise alignment. By utilizing localized stretching strain when gradually laminating a thin microstructured elastomer layer onto a wavy substrate, a pattern is created. To demonstrate this new fabrication process, we laminated a thin polydimethylsiloxane (PDMS) film having a plurality of microstructures thereon, on a wavy PDMS substrate with millimeter-scale inverted pyramidal holes. This resulted in hierarchical surface microstructures that display varying spacings along the peaks and the valleys of the wavy substrate.

Abstract: Described herein are synthetic methods for producing sequence-specific RNA oligonucleotides that eliminate impurities produced in prior art methods. In one aspect, a first amplification primer includes one or more deoxyuridine residues, wherein at least one of the one or more deoxyuridine residues is at position ?1, ?2, ?3, ?4 or ?5 of the promoter region for the single-subunit, DNA-dependent RNA polymerase. The deoxyuridines are excised to provide an amplified functional template DNA which is then used to synthesize RNA which has reduced immunogenic double stranded RNA compared to controls.

Abstract: In some aspects, the disclosure relates to methods for improving titer and yield of viral vector production. In some embodiments, the methods comprise transient silencing of transgene expression during packaging of a viral vector.

Abstract: The invention provides novel polymers, crosslinked polymer-nucleic acid complexes, lipid-polymer-nucleic acid-based complexation and nanoassemblies, and nanoassembly-based intracellular delivery of nucleic acids and controlled release thereof upon degradation of the nanoassemblies in response to specific microenvironment in the cell, and compositions and methods of preparation and use thereof.

Abstract: A first method includes detecting, based on sensor data, an environment state; selecting an action based on the environment state; determining an autonomy level associated with the environment state and the action; and performing the action according to the autonomy level. The autonomy level can be selected based at least on an autonomy model and a feedback model. A second method includes calculating, by solving an extended Stochastic Shortest Path (SSP) problem, a policy for solving a task. The policy can map environment states and autonomy levels to actions and autonomy levels. Calculating the policy can include generating plans that operate across multiple levels of autonomy.

Abstract: A temozolomide compound according to formula (I) is described, wherein R1, L1, and X are defined herein. The temozolomide compound can be used to prepare polymers comprising temozolomide. Additionally, the polymers comprising temozolomide can be particularly useful in the treatment of certain diseases.

Abstract: A true random number generator device based on a diffusive memristor is disclosed. The random number generator device includes a diffusive memristor driven by a pulse generator circuit. The diffusive memristor produces a stochastically switched output signal. A comparator circuit receives the stochastically switched output signal from the diffusive memristor and generates an output signal having a random pulse width. An AND gate logic circuit is driven by a clock signal and the output signal from the comparator circuit. The AND gate logic circuit produces a combined output signal. A counter circuit receives the combined output signal from the AND gate logic circuit and generates a random bit string output signal.

Abstract: Described herein are synthetic methods for producing sequence-specific RNA oligonucleotides that eliminate impurities produced in prior art methods. In one aspect, an end-protected capture DNA complementary to a portion of the product RNA is employed. In another aspect, the template DNA is covalently or noncovalently linked to the RNA polymerase, either directly or through the use of a nontemplate DNA. In a third aspect, a flow chamber is employed. All of the methods can be used in combination.

Abstract: Aspects of the disclosure relate to compositions, such as rAAV vectors, comprising one or more short hairpin nucleic acids positioned outside of the inverted terminal repeats (ITRs) of the rAAV vector (referred to in some embodiments as “stopper DNA”). The disclosure is based, in part, on rAAV vectors comprising stopper DNA, which have improved packaging and/or immunogenicity relative to previously described rAAV vectors. In some embodiments, the disclosure relates to methods of delivering a transgene to a subject comprising administering the rAAV vectors.

Abstract: In some aspects, the disclosure relates to compositions and methods for modulating (e.g., increasing and/or decreasing) bone mass in a subject. In some aspects, the disclosure provides isolated nucleic acids, and vectors such as rAAV vectors, configured to express transgenes that promote (e.g., increase) or inhibit (e.g., decrease) activity, differentiation, or function of certain types of bone cells, for example osteoblasts, osteoclasts, osteocytes, etc. In some embodiments, the isolated nucleic acids and vectors described by the disclosure are useful for treating disorders and conditions associated with increased bone mass (e.g., osteopetrosis) or decreased bone mass (e.g., osteoporosis).

Abstract: In some aspects, the disclosure relates to compositions and methods useful for inhibiting SOD1 expression in cells (e.g., cells of a subject). In some embodiments, the disclosure describes isolated nucleic acids engineered to express an inhibitory nucleic acid targeting endogenous SOD1 and an mRNA encoding a hardened SOD1 protein. In some embodiments, compositions and methods described by the disclosure are useful for treating Amyotrophic Lateral Sclerosis (ALS) in a subject.

Abstract: A system and method for memory allocation and management in non-uniform memory access (“NUMA”) architecture computing environments is disclosed. The system and method contemplates both hardware heterogeneity and allocation/deallocation attributes, with fine-grained memory management. NUMAlloc is centered on a binding-based memory management. On top of it, NUMAlloc proposes an “origin-aware memory management” to ensure the locality of memory allocations and deallocations, as well as a method called “incremental sharing” to balance the performance benefits and memory overhead of using transparent huge pages. It further introduced an interleaved heap to reduce the load imbalance among different nodes and an efficient mechanism for object movement. The system and method provides a scalable and increased performance alternative over other prior art memory allocators.

Abstract: The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

Abstract: In some aspects the disclosure provides compositions and methods for promoting expression of functional NEU1 protein in a subject. In other aspects, the disclosure provides compositions and methods for treating sialidosis, galactosialidosis, and/or Alzheimer's Disease in a subject having or suspected of having sialidosis, galactosialidosis, and/or Alzheimer's Disease.

Abstract: Methods that include inhibition of ROCK1/2 and other protein kinases to treat Friedreich Ataxia.

Abstract: The invention provides novel zwitterionic monomers and polymers (including copolymers) with pendent phosphonium-based zwitterionic moieties, and compositions and products comprising same, as well as related methods and uses of the compositions, for example, as surfactants, coatings, and interlayer materials, biomedical materials or agents.

Abstract: The present disclosure provides, in some aspects, a humanized immunodeficient mouse model of human fibrosis. A humanized immunodeficient mouse model provided herein may be used, for example, for modeling human fibrosis, predicting human fibrosis, and testing putative fibrosis treatments.

Abstract: A new and distinct cultivar of Ageratum plant named ‘Agerboyuma’, characterized by its relatively compact, upright to outwardly spreading and mounding plant habit; moderately vigorous to vigorous growth habit; freely branching habit; relatively large leaves; freely and continuous flowering habit; light violet-colored inflorescences that resist fading; and good garden performance.